As practitioners who prescribe for myopia every day with various forms of refractive correction, we sometimes forget about the significant pathology that can be associated with this disease. Degenerative (or pathological) myopia is a leading cause of blindness, with significant risk for retinal detachment, maculopathies, glaucoma, and early cataracts. Hopefully treatments that control myopia may lead to a reduction in these comorbid visual impairments.
Jason J. Nichols, OD, MPH, PhD
B+L to Launch Ultra Contact Lenses for Presbyopia in Q2 2016
Bausch + Lomb announced that Bausch + Lomb Ultra contact lenses for Presbyopia will become available during the second quarter of 2016. The new multifocal lens was specifically designed to combine the company’s innovative 3-Zone Progressive design, found in Biotrue ONEday for Presbyopia daily disposable contact lenses, with the excellent end-of-day comfort of Bausch + Lomb Ultra contact lenses with MoistureSeal technology.
The announcement of the new B+L Ultra for Presbyopia lens was shared at a Bausch + Lomb B+Lieve event in Boston, MA at which eye care professionals (ECPs) and vision experts from across the country were educated on the latest innovations in vision care, including MoistureSeal technology, the science behind B+L’s latest breakthrough silicone hydrogel lens.
According to the company, B+L Ultra contact lenses with MoistureSeal Technology contain polyvinylpyrrolidone (PVP) for enhanced wettability and have the highest Dk/t (163) and lowest modulus (70) compared to the leading silicone hydrogel contacts lenses in the market. The lens also has aspheric optics, for exceptional vision even in low light conditions.
CLX System Releases My CL Reorder
CLX, a contact lens ordering, managing and marketing system, has introduced enhanced functionality designed to auto e-mail and text patients due to reorder contacts.
My CL Reorder identifies patients due to reorder contact lenses and automatically sends emails or texts prompting them with a link to reorder their prescription contact lenses. Credit card payments are deposited in the practice bank account, and the order is forwarded directly to a preferred practice distributor who then ships the refill directly to the patients.
According to the company, the CLX system is capable of much more than capturing reorder business. Efficient ordering, tracking, and reporting features of CLX also help customers better understand, manage and grow the contact lens side of their business.
CLX System is a cloud-based management platform specifically designed to improve the efficiency and accuracy of contact lens administration as well as to provide valuable data and robust metrics reporting. To learn more, please visit www.CLXsystem.com.
Don’t Miss the 10th Global Specialty Lens Symposium
The 10th Global Specialty Lens Symposium will be held January 21 – 24, 2016 at Caesars Palace Las Vegas, Nevada. The GSLS is a must-attend meeting, brought to you by Contact Lens Spectrum, focusing on the successful management of ocular conditions using today's specialty contact lenses. This meeting will include insightful presentations by international experts in the field, hands-on demonstrations of cutting-edge products and valuable continuing education credits.
The 2015 event was attended by almost 600 registrants from 36 countries, 42 states, Puerto Rico and Guam. It continues to be the largest conference of its kind in the U.S.
Join your peers in 2016 for the 10th anniversary in Las Vegas! Visit www.GSLSymposium.com for more information and to register.
E-Vision Accelerates Development Program for First Fully Tunable Electronic Contact Lens
E-Vision Smart Optics, Inc., a Sarasota-based company specializing in electrically-modulated tunable lens technology, announced that it is developing the first electronic contact lens (ECL) that will allow the wearer to continuously adjust far, near and middle-vision customized to the individual's own needs.
According to the company, this proprietary lens-based technology, already fabricated for electronic focusing eyeglasses, ophthalmic diagnostic equipment and in development with the U.S. military for augmented-reality head mounted displays, will now be integrated into standard contact lens designs.
Several important strategic efforts support e-Vision's accelerated timeline to bring this fully tunable ECL to market. The company recently closed a round of financing within its existing shareholder base to fund this development program. Additionally, the National Space Biomedical Research Institute (NSBRI), a science institute established by NASA, issued e-Vision a grant to develop the first fully tunable electronic eyeglasses to address the deterioration of vision that astronauts experience during space travel.
E-Vision has nearly 550 patents issued or pending worldwide to protect its intellectual property. Its latest patent issued on October 13, 2015 (US 9155614 B2) titled, "Flexible dynamic electro-active lens," provides exclusive use to e-Vision for the use of any flexible lens containing electro-active materials.
According to Joel D. Zychick, President and CEO of e-Vision, the ECL will be the only flexible contact lens giving the end-user the ability to choose from a variety of prescription settings and to dynamically change focus while correcting for a variety of visual impairments, including myopia, hyperopia and higher order aberrations. The first prototype of e-Vision's ECL will be available by late next year.
E-Vision's ECL will have the same look and feel of a traditional flexible contact lens, but it will allow the wearer to select preset focus ranges to change prescription in as little time as 200 milliseconds, according to the company. Featuring the Company's Smart Focus Optics platform technology, the ECL contains an electric field surrounded by a tiny, near invisible layer of liquid crystal material (similar to the screen on a laptop or smart phone). When powered with tiny amounts of electricity (microwatts), uniquely placed electrodes activate the liquid crystal layer and specific optical focus profiles can be achieved. These profiles can create hyperopic or myopic spherical shapes as well as aspheric shapes. E-Vision's ECL power requirements are incredibly efficient so the lens can operate independent of frames or wearable charging stations.
PRN Receives U.S. Patent for Unique 3:1 Omega 3 Composition
Alphaeon Corporation and its subsidiary company PRN Physician Recommended Nutriceuticals, LLC (PRN) announced that the U.S. Patent and Trademark Office issued to PRN U.S. Patent No. 9,115,078 "Compositions for Improving the Quality of the Meibum Composition of Inflamed or Dysfunctional Meibomian Glands."
The patent is another major milestone for PRN. A recent study positively assessed the effect of the company's oral re-esterified triglyceride omega-3 fatty acids for patients with occasional dry eye symptoms. This new 3:1 patented composition delivers a total amount of 2668mg Omega-3 essential fatty acids.
Allergan Submits Prior Approval Supplement for Restasis MDPF Bottle
Allergan plc announced that it has submitted a Prior Approval Supplement (PAS) for Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation. Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of Chronic Dry Eye disease. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
If approved, Restasis in the MDPF bottle offers patients the same formula in a multi-dose system with patented uni-directional valve and air filter technology.
Collected Debris Under Mini-Scleral Lens Ross Collins, OD, Vandalia, Ohio
Anterior segment image of a 16mm diameter mini-scleral lens. This patient suffered from excessive lens reservoir debris that collected near the inferior limbal junction as shown in this image. Patient would describe a gradual "fogging" in her lower vision after 2 hours of wear. This condition was corrected by adding a 2 diopter toric peripheral system in order to better align with the sclera.
We thank Dr. Collins for this image and we welcome photo submissions from our other readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include an explanation of the photo and your full name, degree or title and city/state/country.
The results of a study were recently published that determined the clinical impact of using Systane Balance Lubricant Eye Drops (Alcon, Fort Worth, TX), an oil-in-water emulsion, as a rewetting eye drop in symptomatic contact lens wearers.1 Subjects who had previously experienced contact lens discomfort (CLD), with a mean lens wearing history of 18.6±12.8 years, were randomly assigned to use a Test (Systane Balance Lubricant Eye Drops; n=76) or control (habitual nonlipid contact lens rewetting eye drop; n=30) drop over their contact lenses within 5 minutes of lens insertion and then subsequently at 2 hour intervals up to a maximum of 4 drops per eye daily for a 1-month period. Assessments of subjective comfort, comfortable wearing time, lid wiper epitheliopathy (LWE), and corneal staining were conducted at baseline and after 1 month, after 6 hours of lens wear. Results found that comfort, wearing time, LWE, and corneal staining all showed statistically significant improvements in the test group using Systane Balance Lubricant Eye Drops at the 1-month visit compared with baseline data (all P<0.01) and compared with the control group at the 1-month visit (P<0.01, P=0.01, P<0.01, and P=0.03, respectively). The authors concluded that the use of Systane Balance Lubricant Eye Drops as a rewetting drop in a group of wearers who experienced symptoms of CLD improved subjective comfort scores, increased comfortable wearing time, and reduced signs of LWE and corneal staining, when compared with the use of non-lipid-containing contact lens rewetting eye drops.
1. Guthrie SE, Jones L, Blackie CA, Korb DR. A Comparative Study Between an Oil-in- Water Emulsion and Non-Lipid Eye Drops Used for Rewetting Contact Lenses. Eye Contact Lens. 2015 Nov 41(6): 373-7.
OCULAR SURFACE UPDATE Katherine M. Mastrota, MS, OD, FAAO
When 20/20 Isn’t 20/20
Doctor: “Congratulations Mrs. Patient! Your vision is 20/20”.
Patient: “But Doctor, I can’t see well”.
I know you have had this conversation before. Frustrating, isn’t it?
As a doctor in an educational/optometric referral center, I have unique liberty to gather colleagues to discuss a variety of topics. This month I learned about the Objective Scatter Index (OSI) and how it is quantified to visual measure image degradation. Using “double-pass retinal imaging technology” the OSI is an assessment of the amount of forward light scatter within the eye. The OSI can be quantified by an objective scatter index score that defines visual quality. The examples of high and low OSI scatter were dramatic. Of course, a healthy tear film is integral to clear and stable vision, and its impact on the OSI score is critical. Will the OSI become standard in dry eye evaluations? Could it become the means to measure success in dry eye therapy? The information certainly is valuable and I, like you, will wait and see.
Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia
This article aims to review recent advances in the understanding of epidemiology and risk factors for the development of myopic choroidal neovascularization (CNV) and highlight the diagnostic features of myopic CNV and signs seen on the noninvasive optical coherence tomography technology, which may be particularly useful for the purpose of screening. Choroidal neovascularization is a sight-threatening complication of pathologic myopia. Because myopic CNV frequently affects individuals during their working life, its socioeconomic impact is significant, especially in Asian countries where the prevalence of pathologic myopia is high.
EPIDEMIOLOGY: Pathological myopia is the most common cause of CNV in patients less than 50 years old, and it is estimated that 5.2% to 11.3% of individuals with pathologic myopia develop myopic CNV.
RISK FACTORS: The risk of developing myopic CNV increases with the severity of myopia and macular changes, such as diffuse atrophy, lacquer cracks, and patchy atrophy, which progress to myopic CNV in a significant proportion. Vascular endothelial growth factor (VEGF) may contribute to the development of myopic CNV.
NATURAL COURSE AND PROGNOSIS: Untreated myopic CNV carries a poor visual prognosis, with an estimated 89% of the patients having marked visual impairment within 5 years of onset.
TREATMENT: Anti-VEGF therapy is efficacious in treating myopic CNV. Although this significantly improves the short-term prognosis of myopic CNV, the long-term visual loss due to the sequela of myopic CNV including macular atrophy and scarring remains.
Chan NS, Teo K, Cheung CM. Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia. Eye Contact Lens. 2015 Oct 7. [Epub ahead of print]